No Data
No Data
BeiGene's Q1 Loss Narrows as Revenue Rises
BeiGene (BGNE) reported a Q1 loss Wednesday of $2.41 per American depository share, narrowing from a loss of $3.34 a year earlier.
Hong Kong Stock Announcement Nuggets | BeiGene's total revenue for the first quarter reached US$752 million, up 68% year over year
Meigaoyu (01985) plans to establish two companies, “Meigaoyu Artificial Intelligence” and “Hi-Tech Development” to promote the strategic layout of artificial intelligence...
GLONGHUI ANNOUNCEMENT SELECTION (HK Stock) | BeiGene (06160.HK) Product Revenue Increased by 82% in the First Quarter, R&D Expenses Reached US$460 Million and Ranked Among the Top 15 Global Oncology Treatment Innovators
[Today's Focus] BeiGene (06160.HK)'s product revenue increased 82% in the first quarter, and R&D expenses reached US$460 million, and R&D expenses reached US$460 million. BeiGene (06160.HK) announced that in the first quarter of 2024, the company's total revenue reached US$752 million, of which product revenue reached US$747 million, an increase of 82% over the previous year. Baiyuezer's global sales reached US$489 million, thanks to sales growth of 153% and 243% year-on-year in the US and Europe, respectively; with the recent approval of the FDA for the fifth indication, Baiyuezer has now become
[Hong Kong Stock Connect] BeiGene (06160)'s net profit for the first quarter narrowed 27.9% year over year to US$251 million
Jinwu Financial News | BeiGene (06160) announced that in the first quarter of 2024, a net loss of approximately US$251 million was recorded, a year-on-year decrease of 27.9%. Basic loss per share was $0.19, and ADS basic net loss was $2.41. GAAP net loss improved compared to the same period last year, mainly due to increased product revenue and cost management measures that increased operating leverage efficiency. During the period, total revenue reached US$752 million, up 68% year on year, mainly due to the 153% and 243% year-on-year increase in sales in the US and Europe, respectively. Of these, product revenue reached 747 million US dollars
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
Health care stocks were leaning lower pre-bell Wednesday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.8%. Teva Pharmaceutical Industries
No Data
SpyderCall : Very valuable info as usual. Thanks for the hard work.
shintaka1168 : こんな情報を配信してくれるなんて、おどろきました。これからもチェックしようと思います